Research programme: coronavirus vaccines - Abera Bioscience
Latest Information Update: 30 Aug 2023
Price :
$50 *
At a glance
- Originator Abera Bioscience AB
- Class COVID-19 vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 29 Jun 2023 Research programme: coronavirus vaccines - Abera Bioscience is available for licensing as of 29 Jun 2023. https://aberabio.com/partnering-licensing/
- 29 Jun 2023 Preclinical trials in COVID-2019 infections (Prevention) in Sweden (Intranasal) (Abera Bioscience pipeline, June 2023)